Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There are 2 clinical trials
The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose aiTBS protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with unipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.
Description: Less than or equal to 10
Measure: Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in HRSD-24 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score
Measure: Response on HRSD-24 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 4
Measure: Remission on Patient Health Questionnaire (PHQ-9) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score
Measure: Response on PHQ-9 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in PHQ-9 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 4
Measure: Remission on General Anxiety Disorder 7 item (GAD-7) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in score
Measure: Response on GAD-7 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in GAD-7 Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Less than or equal to 12
Measure: Remission on Beck Depression Inventory (BDI-II) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: 50% Reduction in Score
Measure: Response on BDI-II Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change on BDI-II Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Score of 0
Measure: Remission on Beck Scale for Suicidal Ideation (SSI) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change on SSI Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: changes in scores
Measure: Change in WHO Disability Assessment Schedule (WHODAS) Time: Up to 10 days (From screening/baseline to end of the acute treatment)Description: Includes number of treatment days needed and number going on to receive ECT
Measure: Proportion of Patients Maintaining Response During Relapse Prevention Time: 24 weeks (Tapering and Relapse prevention phase)This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and developing workflows for mental health that are both scalable and personalized.
Description: A repeated measures, within-subject design using exploratory techniques will identify the best group session features or combination of features that correlate with or predict change on the PHQ-9.
Measure: Patient Health Questionnaire (PHQ-9) Time: March 30, 2021Description: A repeated measures, within-subject design using exploratory techniques will identify the best group session features or combination of features that correlate with or predict change on the GAD-7.
Measure: Generalized Anxiety Disorder (GAD-7) Time: June 20, 2021Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports